Baidu
map

心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗

2022-01-16 临床药物基因组学实施联盟 WILEY

氯吡格雷CYP2C19基因型

CYP2C19 催化抗血小板前药氯吡格雷的生物活化，

中文标题：

2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗

发布机构：

临床药物基因组学实施联盟

发布日期：

2022-01-16

简要介绍：

CYP2C19 催化抗血小板前药氯吡格雷的生物活化，CYP2C19基因型影响氯吡格雷活性代谢物的形成。接受氯吡格雷治疗的 CYP2C19 中等和低代谢者会减少血小板抑制，增加主要不良心血管和脑血管事件的风险。本指南是对 2013 年临床药物遗传学实施联盟 (CPIC) 指南的更新，该指南根据CYP2C19基因型使用氯吡格雷，包括扩大CYP2C19基因型指导的抗血小板治疗的适应症，增加对 CYP2C19 中间代谢物的推荐强度，更新CYP2C19基因型到表型的翻译，以及来自扩展文献综述的证据。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=faa3e1c002323137, title=2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗, enTitle=, guiderFrom=WILEY, authorId=0, author=, summary=CYP2C19 催化抗血小板前药氯吡格雷的生物活化，, cover=https://img.medsci.cn/2022116/1642345609343_1608702.jpg, journalId=0, articlesId=null, associationId=1236, associationName=临床药物基因组学实施联盟, associationIntro=, copyright=0, guiderPublishedTime=Sun Jan 16 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #1c1d1e;"><span>CYP2C19 催化抗血小板前药氯吡格雷的生物活化，</span></span><em style="color: #1c1d1e;"><span>CYP2C19</span></em><span style="color: #1c1d1e;"><span>基因型影响氯吡格雷活性代谢物的形成。</span><span>接受氯吡格雷治疗的 CYP2C19 中等和低代谢者会减少血小板抑制，增加主要不良心血管和脑血管事件的风险。</span><span>本指南是对 2013 年临床药物遗传学实施联盟 (CPIC) 指南的更新，该指南根据</span></span><em style="color: #1c1d1e;"><span>CYP2C19</span></em><span style="color: #1c1d1e;"><span>基因型使用氯吡格雷，包括扩大</span></span><em style="color: #1c1d1e;"><span>CYP2C19</span></em><span style="color: #1c1d1e;"><span>基因型指导的抗血小板治疗的适应症，增加对 CYP2C19 中间代谢物的推荐强度，更新</span></span><em style="color: #1c1d1e;"><span>CYP2C19</span></em><span style="color: #1c1d1e;"><span>基因型到表型的翻译，以及来自扩展文献综述的证据。</span></span></p>, tagList=[TagDto(tagId=504, tagName=氯吡格雷), TagDto(tagId=62517, tagName=CYP2C19基因型)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6510, appHits=124, showAppHits=0, pcHits=1543, showPcHits=6385, likes=1, shares=13, comments=12, approvalStatus=1, publishedTime=Sun Jan 16 23:01:35 CST 2022, publishedTimeString=2022-01-16, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Sun Jan 16 23:09:09 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 21:22:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗.pdf)])
2022 年更新 临床药物遗传学实施联盟指南：CYP2C19基因型和氯吡格雷治疗.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198020, encodeId=c225119802052, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3db1761596, createdName=ms5833112425946735, createdTime=Mon Feb 28 14:50:21 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193899, encodeId=6dc91193899d1, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:18 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192369, encodeId=7f3d119236995, content=振奋人心, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6375152963, createdName=1469de7am99(暂无昵称), createdTime=Fri Feb 11 16:26:08 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186813, encodeId=0b501186813d3, content=学习了，真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:20 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185829, encodeId=1a2f118582946, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea56419271, createdName=ms8000001795365678, createdTime=Tue Jan 18 23:53:30 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-02-28 ms5833112425946735

    认真学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198020, encodeId=c225119802052, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3db1761596, createdName=ms5833112425946735, createdTime=Mon Feb 28 14:50:21 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193899, encodeId=6dc91193899d1, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:18 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192369, encodeId=7f3d119236995, content=振奋人心, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6375152963, createdName=1469de7am99(暂无昵称), createdTime=Fri Feb 11 16:26:08 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186813, encodeId=0b501186813d3, content=学习了，真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:20 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185829, encodeId=1a2f118582946, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea56419271, createdName=ms8000001795365678, createdTime=Tue Jan 18 23:53:30 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-02-16 龙珠

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198020, encodeId=c225119802052, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3db1761596, createdName=ms5833112425946735, createdTime=Mon Feb 28 14:50:21 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193899, encodeId=6dc91193899d1, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:18 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192369, encodeId=7f3d119236995, content=振奋人心, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6375152963, createdName=1469de7am99(暂无昵称), createdTime=Fri Feb 11 16:26:08 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186813, encodeId=0b501186813d3, content=学习了，真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:20 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185829, encodeId=1a2f118582946, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea56419271, createdName=ms8000001795365678, createdTime=Tue Jan 18 23:53:30 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-02-11 1469de7am99(暂无昵称)

    振奋人心

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198020, encodeId=c225119802052, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3db1761596, createdName=ms5833112425946735, createdTime=Mon Feb 28 14:50:21 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193899, encodeId=6dc91193899d1, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:18 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192369, encodeId=7f3d119236995, content=振奋人心, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6375152963, createdName=1469de7am99(暂无昵称), createdTime=Fri Feb 11 16:26:08 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186813, encodeId=0b501186813d3, content=学习了，真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:20 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185829, encodeId=1a2f118582946, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea56419271, createdName=ms8000001795365678, createdTime=Tue Jan 18 23:53:30 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-21 ms1000001107271726

    学习了，真好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1198020, encodeId=c225119802052, content=认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3db1761596, createdName=ms5833112425946735, createdTime=Mon Feb 28 14:50:21 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193899, encodeId=6dc91193899d1, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Wed Feb 16 08:55:18 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192369, encodeId=7f3d119236995, content=振奋人心, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d6375152963, createdName=1469de7am99(暂无昵称), createdTime=Fri Feb 11 16:26:08 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186813, encodeId=0b501186813d3, content=学习了，真好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=457d5614441, createdName=ms1000001107271726, createdTime=Fri Jan 21 14:09:20 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185829, encodeId=1a2f118582946, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea56419271, createdName=ms8000001795365678, createdTime=Tue Jan 18 23:53:30 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 ms8000001795365678

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 临床实践指南：急性高危短暂性脑缺血发作和轻型缺血性卒中应用阿司匹林和氯吡格雷进行双抗治疗

国外神经外科相关专家小组（统称） · 2018-12-18

Baidu
map
Baidu
map
Baidu
map